echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: The effect of Tapinarof cream in the treatment of plaque psoriasis

    NEJM: The effect of Tapinarof cream in the treatment of plaque psoriasis

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tapinarof cream is a topical aromatic hydrocarbon receptor modulator, which is being studied for the treatment of psoriasis
    .
    Tapinarof cream can regulate the expression of interleukin 17 and skin barrier proteins filaggrin and loricrin
    .

    Recently, the top medical journal NEJM published a research article in which researchers conducted two identical phase 3 randomized trials in patients with mild to severe plaque psoriasis
    .
    Patients with a baseline physician’s overall assessment (PGA) score of 2 (mild) to 4 (severe) (range 0 to 4, the higher the score, the more severe the psoriasis) and the area of ​​the disease that accounts for 3 to 20% of the total surface area is 2 The ratio of 1: 1 was randomly assigned to use 1% tapinarof cream or control cream once a day for 12 weeks of continuous treatment
    .

    The primary endpoint of the study was the PGA response, that is, a PGA score of 0 (cleared) or 1 (almost cleared) and a decrease of at least 2 points from baseline at week 12
    .
    The secondary efficacy endpoint of the study is a reduction of at least 75% in the Psoriasis Area and Severity Index (PASI) score, a PGA score of 0 or 1, the average change in the percentage of affected body surface area from baseline, and a reduction in the PASI score of at least 90 %
    .
    The outcome reported by the patient is from baseline to week 12, in the peak pruritus numerical rating scale (PP-NRS) score (range 0 [no itch] to 10 [worst pruritus]), PP-NRS total score, skin Total disease quality of life index score and psoriasis symptom diary score
    .

    Quality of Life

    In trials 1 and 2, the study screened a total of 692 and 674 patients, respectively, of which 510 and 515 patients were included
    .
    In trial 1, 35.
    4% of the patients in the Tapinarof ointment group and 6.
    0% of the patients in the control group had a PGA response, while in trial 2, 40.
    2% and 6.
    3%, respectively (P<0.
    001 for the two comparisons)
    .
    The secondary endpoints and patient-reported outcomes are the same as the primary endpoints
    .
    Adverse reactions of Tapinarof cream include folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection and itching
    .

    Infect

    It can be seen that in the 12-week treatment period, 1% Tapinarof cream once a day is better than the control ointment in reducing the severity of plaque psoriasis, but it is related to local adverse events and headaches
    .
    Compared with existing treatments for psoriasis, larger and longer-term trials are needed to evaluate the efficacy and safety of Tapinarof cream
    .

    During the 12-week treatment period, 1% Tapinarof cream once a day was better than the control ointment in reducing the severity of plaque psoriasis, but was related to local adverse events and headaches
    .
    Compared with existing treatments for psoriasis, larger and longer-term trials are needed to evaluate the efficacy and safety of Tapinarof cream
    .

    Original source:
     
    Mark G.
    Lebwohl, et al.
    Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis .
    NEJM.
    2021.
    https:// source: Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis Leave a message here


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.